{"id":"W2755831795","doi":"10.1016/j.jaad.2017.06.153","title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; SKiN Health","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Plaque psoriasis; Psoriasis; Randomized controlled trial; Clinical trial; Dermatology; Internal medicine; Secukinumab; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005443084,0.001428093,0.00209964,0.0002623429,0.000447163,0.0009266157,0.0007378978,0.00117446,0.003112372],"category_scores_gemma":[0.002540398,0.0004421908,0.002413727,0.0003263561,0.0009170321,0.0007975043,0.000391815,0.002485067,0.0004626514],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006240984,"about_ca_system_score_gemma":0.001329371,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007135746,"about_ca_topic_score_gemma":0.00159158,"domain_scores_codex":[0.9983394,0.001051673,0.00009018916,0.000182306,0.000141986,0.0001944101],"domain_scores_gemma":[0.9981129,0.0004998869,0.0006212474,0.0001761378,0.0001047451,0.000485118],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9662996,0.008407803,0.00241963,0.0003408092,0.0009260254,0.00003168384,0.00006320294,0.0003743747,0.003164145,0.00006000415,0.0008239642,0.01708882],"study_design_scores_gemma":[0.8807318,0.1067562,0.009621579,0.00003520859,0.0007939412,0.00006610317,0.00002480505,0.0005060031,0.0006972408,0.0001531842,0.0005943074,0.00001972049],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918661,0.00276003,0.0006390585,0.0003786542,0.0001352391,0.002000224,0.001129878,0.00009257991,0.0009981957],"genre_scores_gemma":[0.9902353,0.001745317,0.001608875,0.0005487031,0.0002600615,0.002931293,0.001473638,0.00003171429,0.001165114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005443084,"threshold_uncertainty_score":0.02878612,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04825524568326119,"score_gpt":0.3700946110253621,"score_spread":0.3218393653421009,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}